These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 536276)

  • 1. Combined therapy with an aziridine derivative NSC 200724 (AB182) and radiation on an experimental leukemia.
    Wodinsky I; Clement J; Swiniarski J; Skura A
    Int J Radiat Oncol Biol Phys; 1979 Sep; 5(9):1677-80. PubMed ID: 536276
    [No Abstract]   [Full Text] [Related]  

  • 2. Interaction of gamma-irradiation with two new antineoplastic agents, aziridinylbenzoquinone (AZQ) and 4'- (acridinylamino)methanesulfon-m-anisidide (AMSA), in murine tumors in vivo.
    Johnson RK; Wodinsky I; Swiniarski J; Meaney KF; Clement JJ
    Int J Radiat Oncol Biol Phys; 1979 Sep; 5(9):1605-9. PubMed ID: 583418
    [No Abstract]   [Full Text] [Related]  

  • 3. Radiation potentiating effect of ethyl bis(2,2-dimethyl-1-aziridinyl) phosphinate (AB-163).
    Wampler GL; Wassum JA; Belgrad R
    Int J Radiat Oncol Biol Phys; 1979 Sep; 5(9):1681-3. PubMed ID: 536277
    [No Abstract]   [Full Text] [Related]  

  • 4. Antitumour activity of some cyclophosphazenes.
    Labarre JF; Faucher JP; Levy G; Sournies F; Cros S; François G
    Eur J Cancer (1965); 1979 May; 15(5):637-43. PubMed ID: 510331
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacological evaluation of combination therapy of P388 leukemia with cyclophosphamide and pyrimidinones.
    Li LH; Wallace TL; Hamilton RD; DeKoning TF
    Int J Immunopharmacol; 1987; 9(1):31-9. PubMed ID: 3583503
    [No Abstract]   [Full Text] [Related]  

  • 6. Synthesis and properties of bis(2,2-dimethylaziridinyl)phosphinic amides: a series of new antineoplastic agents.
    MacDiarmid JE; Rose WC; Biddle WC; Perlman ME; Breiner RG; Ambrus JL; Bardos TJ
    J Med Chem; 1985 Nov; 28(11):1685-91. PubMed ID: 4067995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitization of anoxic mouse tumours to x-rays with diamide and nifuroxime.
    Harris JW; Wara WM; Kane LJ
    Int J Radiat Biol Relat Stud Phys Chem Med; 1974 Sep; 26(3):227-35. PubMed ID: 4547754
    [No Abstract]   [Full Text] [Related]  

  • 8. The antineoplastic activity of hexaziridinocyclotriphosphazene (Myko 63) in murine tumors.
    Malfiore C; Marmonti L; Filippeschi S; Labarre JF; Spreafico F
    Anticancer Res; 1983; 3(6):425-9. PubMed ID: 6230986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 3'-amino-3'-deoxythymidine on L1210 and P388 leukemias in mice.
    Lin TS; Fischer PH; Prusoff WH
    Biochem Pharmacol; 1982 Jan; 31(1):125-8. PubMed ID: 7059345
    [No Abstract]   [Full Text] [Related]  

  • 10. Synthesis of potential dual-acting radiation sensitizer antineoplastic agents: 2,2-dimethylphosphoraziridines containing 2-nitroimidazoles or other electron-affinic moieties.
    Perlman ME; Dunn JA; Piscitelli TA; Earle J; Rose WC; Wampler GL; MacDiarmid JE; Bardos TJ
    J Med Chem; 1991 Apr; 34(4):1400-7. PubMed ID: 2016716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results of experimental and clinical studies of a new antileukemic drug: hexaphosphamide. Review of the literature and the author's own results].
    Khomchenovskii EI
    Haematologia (Budap); 1977; 11(1-2):115-26. PubMed ID: 352850
    [No Abstract]   [Full Text] [Related]  

  • 12. Radiation sensitizing agents in clinical radiation and chemotherapy.
    Ambrus JL; Ambrus CM; Bardos TJ; Chmielewicz ZF
    J Med; 1980; 11(1):29-38. PubMed ID: 6156977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo circumvention of vincristine resistance in mice with P388 leukemia using a novel compound, AHC-52.
    Shinoda H; Inaba M; Tsuruo T
    Cancer Res; 1989 Apr; 49(7):1722-6. PubMed ID: 2924316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of antitumor action of pyrimidinones in the treatment of B16 melanoma and P388 leukemia.
    Li LH; Wallace TL; Richard KA; Tracey DE
    Cancer Res; 1985 Feb; 45(2):532-8. PubMed ID: 3967227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of P388 leukemia with benzaldehyde.
    Balázová E; Koza I
    Neoplasma; 1988; 35(6):725-8. PubMed ID: 3221939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of melphalan activity in the KHT sarcoma by the radiosensitizer RSU 1069.
    Siemann DW; Maddison K; Wolf K
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1657-60. PubMed ID: 6548212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
    Borden EC; Sidky YA; Hatcher JF; Bryan GT
    Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo response of mitoxantrone and doxorubicin with dipyrone in parental and doxorubicin-resistant P388 leukemia.
    Kamath NS; Chitnis MP
    Oncology; 1990; 47(2):166-9. PubMed ID: 2314829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cure of mice bearing P388 leukemia by vincristine in combination with a calcium channel blocker.
    Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y
    Cancer Treat Rep; 1985 May; 69(5):523-5. PubMed ID: 4005874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of finoptin on doxorubicin accumulation in leukemia P-388 cells with induced resistance to the combination of finoptin and doxorubicin].
    Moroz LV; Donenko FV; Borovkova NB; Sitdikova SM; Kabieva AO
    Biull Eksp Biol Med; 1990 Mar; 109(3):290-2. PubMed ID: 2364157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.